Sinovac Biotech Ltd. ( NASDAQ:SVA). Last Market Price: 2.97, Change: +0.61, % Change: (25.85%). Shares trade in the range of 2.42 - 3.33 dollars. It has a market capitalization of 162.28M dollars, making it a Small Cap Stock and has 54.64M outstanding shares. The company has a beta of 2.25, indicating, the stock to be more volatile than the market. As per the most recent quarterly report, the net income per share (EPS) is -0.2. It operates in Healthcare sector and belongs to Biotechnology and Drugs industry. Percentage shares held by institutional investors is 49%. The company has a 52 week high of $ 5.06 and a 52 week low of $ 1.91. Average volumes of shares traded daily are 130,208. Volume traded in the last session was at 1,190,000, 9.14 times the average volume.

For Q2 (Jun '11), It had a Net profit margin of 11.99%, an Operating margin of 20.00%. Other Key stats and ratios are : Return on average assets of 3.71%, Return on average equity of 4.21%. The organization has an employee strength of 483

Senior management consists of Weidong Yin, ( Age: 46 ), as Chairman of the Board, President, Chief Executive Officer, Secretary, Nan Wang, ( Age: 44 ), as Interim Chief Financial Officer, VP - Business Development; General Manager of Sinovac Dalian and Xia Ming, ( Age: 37 ), as Vice President - Sales and Marketing of Sinovac Beijing. Zhenshan Zhang, ( Age: 36 ), as General Manager of Tanghsn Yian Kenneth Lee as Director

Consensus Recommendation is a Hold.

Estimate for sales for the Quarter Ending Sep-11 show a mean of 12.10 million dollars, an estimate high of 12.10 million dollars and an estimate low of 12.10 million dollars. A year ago the figures stood at 24.69 million dollars.

Estimate for sales for the Quarter Ending Dec-11 show a mean of 27.24 million dollars, an estimate high of 27.24 million dollars and an estimate low of 27.24 million dollars. A year ago the figures stood at 43.42 million dollars.

Estimate for EPS for the Quarter Ending Sep-11 show a mean of 0.00 dollars, an estimate high of 0.02 dollars and an estimate low of -0.01 dollars. A year ago the figures stood at 0.08 dollars.

Estimate for EPS for the Quarter Ending Dec-11 show a mean of 0.19 dollars, an estimate high of 0.24 dollars and an estimate low of 0.14 dollars. A year ago the figures stood at 0.08 dollars.

Sales for Quarter Ending Jun-11 was estimated at 5.66 million dollars, however the actual sales figure stood at 15.66 million dollars, 9.99 million dollars more than estimates.

Sales for Quarter Ending Mar-11 was estimated at 4.52 million dollars, however the actual sales figure stood at 4.68 million dollars, 0.16 million dollars more than estimates.

Read more: http://www.beaconequity.com/smw/11981/Sinovac-Biotech-Key-stats-and-ratios#ixzz1WZShTNtM